UR 12670

Subscribe to Selected New Research on UR 12670

5 relevant articles (2 outcomes, 0 trials/studies) found for this Bio-Agent

Description: structure in first source

Also Known As:

1-((1-(3,3-diphenylpropanoyl)-4-piperidyl)methyl)-1H-2-methylimidazo(4,5-c)pyridine; UR-12670

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

Related Diseases

1.	Necrosis 03/01/2003 - "Continuous administration of UR-12670 improved the histological pattern of liver xenografts, especially necrosis, loss of hepatocytes, hemorrhage, sinusoidal congestion and lymphocyte infiltration" Get all the results and reference details, order at left...
2.	Acute Kidney Failure (Acute Renal Failure) 11/01/1999 - "RESULTS: UR-12670 administration exerted functional and morphological protection against post-ischemic acute renal failure" Get all the results and reference details, order at left...
3.	Hemorrhage 03/01/2003 - "Continuous administration of UR-12670 improved the histological pattern of liver xenografts, especially necrosis, loss of hepatocytes, hemorrhage, sinusoidal congestion and lymphocyte infiltration" Get all the results and reference details, order at left...
4.	Reperfusion Injury 04/01/2001 - "CONCLUSIONS: The chronic administration of the PAF antagonist UR-12670 attenuates the long-term effects of ischaemia-reperfusion injury in uninephrectomized ageing rats" 11/01/1999 - "CONCLUSION: The chronic administration of the PAF antagonist UR-12670 attenuates the long-term effects of ischemia-reperfusion injury in uninephrectomized rats" Get all the results and reference details, order at left...
5.	Endotoxemia 01/01/1997 - "UR-12670 protected against several shock symptoms, confirming the role of PAF in the pathogenesis of rodent endotoxemia." 01/01/1997 - "UR-12670 is a novel and potent PAF antagonist, eg., it displaces [3H]WEB-2086 from PAF receptors in rabbit platelet membranes (Ki = 0.6 nM) and inhibits PAF-induced increase in vascular permeability in rat trachea (100%), thymus (44%), seminal vesicles (100%) and stomach (54%) at a dose of 0.01 mg/kg i.v. Since PAF is thought to be an important mediator in endotoxic shock, the effect of pretreatment with UR-12670 on changes in vascular permeability, disseminated intravascular coagulation (DIC) and plasma biochemical parameters were determined in a rat model of acute endotoxemia" Get all the results and reference details, order at left...
11 Diseases and 5 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Platelet Activating Factor
2.	Dacarbazine (DIC)
3.	WEB 2086 (apafant)
4.	platelet activating factor receptor
4 Drugs and Important Bio-Agents and 1 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
1 Therapies and Procedures and 1 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>